Effect of Amprya (Fampridine-PR (prolonged released 4-aminopyridine)) on the manual functions of patients with MS: STUDY

Image Source: HEALTH

Fampyra: Multiple Sclerosis patient welcomes claims that HSE looks set to fund a miracle drug

Gerard Murphy at the Royal Hospital in Donnybrook, Dublin

A Multiple Sclerosis patient has welcomed claims that the HSE looks set to fund a miracle drug.

Multiple Sclerosis sufferer blasts 'cruel' HSE for refusing to make wonder drug Fampyra free

Gerard Murphy at the Royal Hospital in Donnybrook , Dublin

A Multiple Sclerosis sufferer who was the first in the country to avail of a trial wonder drug has blasted the “cruel” HSE for refusing to make it widely available for free.

Relationship Between Timed 25-Foot Walk Impairment and Diffusion Tensor Imaging Markers in Multiple Sclerosis: STUDY

Image source: http://article.wn.com/

Long-term safety and efficacy of Ampyra (dalfampridine) for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials: STUDY

Ampyra (Dalfampridine) Effects Beyond Walking Speed in Multiple Sclerosis: Results from the STEADY Study: STUDY

Long-term safety and efficacy of Ampyra (dalfampridine) for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials: STUDY

Prescriber utilization of Ampyra (dalfampridine) extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis: STUDY

Denis Naughten, TD, believes Ireland should be a pilot country for State-funded multiple sclerosis drug

Denis Naughten, TD

The Health Service Executive has rejected a second application from the makers of a drug that helps people with multiple sclerosis to walk to have it covered by State-funded drug schemes.

VIDEO: Ampyra helps MS patients to walk again

Click here to watch video

Medicinal marijuana drug means end to buying drugs on the street

The signing off of the introduction of a medicinal marijuana product, Savitex, in Ireland has been welcomed by Tom Curran, partner of the late Marie Fleming.

Wow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR

Teva soaring out in front on a single product and it is no surprise that the Generics pack are waiting in the rear ready for the copaxone patents to expire starting May 2014. However Biogen are backing the most winners with a staggering $5.8 billion worth of business. 

#1 Glaterimer acetate Teva     $4.3 billion
#2 Avonex Biogen Idec           $3.0 billion
#3 Gilenya Novartis                 $1.9 billion
#4 Tysabri Biogen  Idec           $1.7 billion
#5 Betaseron Bayer                 $1.1 billion
#6 Tecfidera Biogen Idec        $0.9 billion
#7 Rebif EMD serono              $0.6 billion
#8 Ampyra Biogen Idec           $0.3 billion
#9 Aubagio Sanofi                   $0.2 billion
#10 Extavia Novartis               $0.2 billion

Tecfidera and Ampyra Show Potential for Quality of Life Improvement in Patients With MS

Tecfidera and Ampyra Show Potential for Quality of Life Improvement in Patients With MS

New disease-modifying drugs in multiple sclerosis (MS) show potential for improving quality-of-life (QoL) of patients with multiple sclerosis. The clinical benefits of dimethyl fumarate and PR-fampridine were discussed at a Biogen Idec-sponsored satellite symposium at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Neurologists mad about British guidance on MS drugs Fampyra, Sativex

Click here to read